Skip to main content
TipRanks
Go Ultimate75% OFF

Syngen Biotech Co., Ltd. (8279) AI Stock Analysis

TW:8279

Syngen Biotech Co., Ltd.

(TPEx:8279)

Select Model
Rating:56Neutral
Price Target:TWD 83.00â–²(4.67% Upside)
Action:initiatedcoverage
Date:11/10/26

The overall score of 56 reflects a company with a solid financial foundation but facing significant operational headwinds. The primary drag is the severe revenue contraction highlighted in the income statement, which is confirmed by a bearish technical trend with the stock trading below all major moving averages. These weaknesses are partially offset by a very strong, low-debt balance sheet and an attractive valuation with a low P/E and high dividend yield, which may provide a floor for the stock.

Positive Factors
Conservative balance sheetVery low leverage gives Syngen Biotech meaningful financial flexibility as operating conditions fluctuate. A large equity-funded capital base limits balance-sheet risk, supports continued investment in diagnostic capabilities, and reduces pressure from debt servicing over the next several quarters.
Negative Factors
Material revenue contractionThe sharp TTM revenue decline signals weakened demand or business activity across the company’s current operations. If the contraction persists, it could reduce operating leverage, limit reinvestment capacity, and make it harder for Syngen Biotech to restore prior growth trends.

Syngen Biotech Co., Ltd. (8279) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%TW:8279-35.11%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 2.15B
Dividend Yield
6.31%
Average Volume (3M)
40.93K
Price to Earnings (P/E)
10.5
Beta (1Y)
0.19
Revenue Growth
-3.92%
EPS Growth
-29.93%
Country
TW
Employees
554
Sector
General
Sector Strength
55
Industry
Biotechnology

Syngen Biotech Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 1988 and based in Tainan City, Taiwan, Syngen Biotech Co.,Ltd. operates globally, including in Taiwan and China, specializing in the research, development, production, and sale of a diverse array of products. Its core offerings include...

Syngen Biotech Co., Ltd. Financial Statement Overview

Summary

Financial performance is mixed. A strong balance sheet (Score: 78) with low debt provides stability, but the income statement (Score: 35) shows a sharp 24.7% revenue decline and margin compression. Cash flow (Score: 65) is adequate but inconsistent. The overall financial health is weighed down significantly by deteriorating top-line growth.

Income Statement

35Negative

Balance Sheet

78Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.05B2.14B2.01B1.84B1.93B1.47B
Gross Profit635.67M723.59M723.94M643.92M688.15M528.34M
EBITDA333.78M448.31M423.57M442.14M448.88M380.42M
Net Income204.72M271.59M240.21M274.83M321.24M237.77M
Balance Sheet
Total Assets3.14B3.05B3.08B3.11B3.07B2.42B
Cash, Cash Equivalents and Short-Term Investments322.49M275.46M341.93M366.89M246.05M314.80M
Total Debt338.68M315.59M544.80M681.76M786.53M236.08M
Total Liabilities735.85M674.89M848.52M974.63M1.08B644.16M
Stockholders Equity2.40B2.37B2.24B2.13B1.99B1.77B
Cash Flow
Free Cash Flow319.45M243.07M283.70M321.33M-307.23M274.83M
Operating Cash Flow401.93M319.48M348.04M415.13M277.48M336.50M
Investing Cash Flow-82.75M-76.83M-84.53M-93.68M-585.05M-336.07M
Financing Cash Flow-280.34M-309.47M-289.09M-200.54M238.75M-108.88M

Syngen Biotech Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price79.30

Price Trends

50DMA80.02Negative
100DMA83.66Negative
200DMA93.34Negative

Market Momentum

MACD-0.10Positive
RSI42.41Neutral
STOCH27.36Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:8279, the sentiment is Negative. The current price of 79.30 is below the 20-day moving average (MA) of 80.90, below the 50-day MA of 80.02, and below the 200-day MA of 93.34, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 42.41 is Neutral, neither overbought nor oversold. The STOCH value of 27.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TW:8279.

Syngen Biotech Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:8279 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:8432TW:843286OutperformTWD 2.36B11.24―4.25%20.56%67.85%
TW:8279TW:827956NeutralTWD 2.15B10.47―6.31%-3.92%-29.93%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:4108TW:410847NeutralTWD 2.02B-74.69――1.10%54.83%

* General Sector Average

Performance Comparison

-50%0%50%TW:8279TW:4108TW:6932TW:7731TW:7860TW:8432Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:8279 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:8279Syngen Biotech Co., Ltd.79.30-43.38-35.36%
TW:4108Phytohealth Corporation10.15-3.85-27.50%
TW:6932Merdury Biopharmaceutical Corporation5.21-4.58-46.78%
TW:7731MARX Biotech Co., Ltd.4.07-0.80-16.36%
TW:7860Teh Seng Pharmaceutical Mfg Co Ltd77.7010.1815.07%
TW:8432TSH Biopharm Corp. Ltd.61.4011.8623.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026